Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma
O. Becquart(Centre Hospitalier Universitaire de Montpellier), B. Guillot(Université de Montpellier), M. Beylot‐Barry(Université de Bordeaux), Bastien Oriano(Hôtel-Dieu de Paris), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), Célèste Lebbé(Inserm), S. Dalac(CHU Dijon Bourgogne), Jean‐Philippe Arnault(Centre Hospitalier Universitaire Amiens-Picardie), Thierry Lesimple, Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Henri Montaudié(Hôpital l'Archet), F. Brunet‐Possenti(Inserm), F. Aubin(Centre Hospitalier Universitaire de Besançon), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Raphaël Porcher(Hotel Dieu Hospital), Stéphane Dalle(Hospices Civils de Lyon), Laurent Mortier, Julie De Quatrebarbes(Centre Hospitalier Annecy Genevois), Pierre‐Emmanuel Stoebner(Centre Hospitalier Universitaire de Nîmes), Brigitte Dréno(Nantes Université)
Cited by 6
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k